Why Thermal Vaporisation is the Next Frontier in Inhaled Drug Delivery

By The Alveon Team

---

8 April 2026 - Pulmonary drug delivery is at a crossroads. While pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs) have shaped respiratory medicine for decades, both technologies are increasingly showing their limits when applied to modern, complex molecules. The obstacle is rarely the active pharmaceutical ingredient (API) itself. It is, more often, everything around it: the lactose carriers, chemical propellants, and inconsistent aerosol characteristics that define legacy systems and complicate reproducible dosing.

In an era where precision medicine is the expected standard, the field requires a delivery mechanism that is as controlled as the molecules it carries. Thermal vaporisation of liquid actives (the principle underlying Alveon's Smart Dose Vaporisation (SDV) platform) offers a technically robust answer to that challenge. Crucially, it does so while satisfying the increasingly stringent requirements of the EU Medical Device Regulation (EU MDR).

Image: unsplash / CNordic Nordic

The Case Against Excipients: Why Carrier-Free Delivery Matters

A structural limitation of conventional inhalation systems is their dependence on excipients. In DPIs, lactose carriers are required to achieve flowability and detachment of the active particle from the carrier surface during inhalation. In pMDIs, hydrofluorocarbon propellants drive aerosol generation. Both introduce variables: local irritation, cough reflex, and fluctuating bioavailability across patients and inhalation techniques.

The SDV platform removes this layer entirely. Through precisely calibrated thermal control of a patented ceramic dosing element, the API is converted into a high-purity vapour aerosol  — whether a complex botanical extract or a synthetic compound. No combustion. No carrier material. No mechanical atomisation force that could compromise molecular integrity. The delivered aerosol contains the therapeutic compound and nothing else, which simplifies both the pharmacokinetic profile and the regulatory documentation required to characterise it.

For pharmaceutical developers, this translates to a cleaner formulation space: fewer excipient-related variables to control, a more straightforward safety and tolerability dossier, and a delivery mechanism whose performance is determined by the device rather than by patient inhalation technique.

Dosing Precision in Thermal Vaporisation: Meeting and Exceeding Pharmacopoeial Standards

Historically, the credibility gap for thermal vaporisation in clinical settings has centred on dosing reliability. The concern is legitimate: if delivered dose varies materially across inhalation cycles or as a cartridge approaches end-of-life, the technology cannot support therapeutic applications where dosing margins are tight.

The European Pharmacopoeia (Ph. Eur.) sets a permitted variance of ±25% for delivered dose uniformity. This threshold exists because it represents a clinically meaningful boundary. Beyond it, the gap between intended and actual dose becomes therapeutically significant. Many vaporisation systems, particularly those designed for consumer use, do not meet this standard under standardised test conditions. Under the EU MDR, this is not a technicality: particle size and delivery consistency constitute "essential performance data" for inhaler classification. A device that cannot demonstrate adequate performance in this domain cannot achieve MDR compliance and therefore cannot function as a prescription medical device, regardless of its other characteristics.

The Alveon SDV platform has demonstrated a delivered dose variance of ±10% in testing conducted at ACTARMO, a specialist aerosol research facility. This performance was achieved using high-viscosity CBD extract in ethanol across n=35 measurements which is a substance chosen specifically because its viscosity profile makes consistent dosing technically demanding. Staying within ±10% under these conditions establishes a meaningful performance margin above the Ph. Eur. threshold and provides an evidence base that is directly relevant to regulatory submissions.

Particle Size: The Physics of Pulmonary Deposition

Aerosol therapeutics depend on a fundamental physical constraint: to reach the alveolar region of the lung, where the surface area available for gas exchange approaches 70 m², particles must fall within a defined size range. Particles that are too large deposit in the oropharynx and are swallowed rather than absorbed systemically. Particles that are too small are exhaled before meaningful deposition occurs.

Established guidance from regulatory bodies including the EMA as well as extensive literature on inhaled pharmacokinetics identifies the fine particle fraction (FPF) in the approximately 1–5 µm range as the primary determinant of deep lung deposition. ACTARMO testing of the SDV platform confirmed that the Alveon ceramic dosing mechanism can adjust particle size through proprietary means to consistently target this optimal window across a range of API formulations and dose levels.

By contrast, comparative data shows that conventional cannabis vaporisation devices, including medically approved products such as the Volcano Medic, produce particle size distributions significantly below this optimal range (measured at approximately 0.64 µm), leading to proportionally lower alveolar deposition. Based on the particle size data generated to date, lung deposition with the SDV platform is projected to at least double compared to these reference technologies. For pharmaceutical partners, the implications are direct: lower API requirements for equivalent therapeutic effect, a narrower systemic exposure range, and a more predictable onset profile — all of which reduce the complexity of dose-finding in clinical development.

Regulatory Pathway: From Performance Data to Market Access

Alveon's position is that technical performance and regulatory readiness are not sequential: They are the same process. The SDV platform is being developed in full alignment with the EU MDR Class IIa certification pathway, with device development, quality management, and documentation structured to meet the standards required for prescription-grade medical device status.

The distinction between a compliant medical inhaler and a consumer vaporisation product is not primarily a matter of branding or intended use. It is a matter of demonstrable performance. Under EU MDR, essential performance data, including delivered dose uniformity and particle size characterisation, must be generated, documented, and defensible. Devices that cannot satisfy these requirements cannot achieve MDR compliance. This regulatory reality effectively draws a hard line between the consumer vaping market and the medical device space, and the SDV platform is engineered to be on the right side of that line.

For pharmaceutical partners considering pulmonary delivery for a novel or reformulated API, this matters at the level of development strategy. A delivery platform that arrives with a pre-existing performance data package, including Ph. Eur. dose uniformity data, particle size characterisation across viscosity profiles, and a quality management system developed to ISO 13485 standards, materially reduces the regulatory burden on the clinical programme. The platform provides the validated technical foundation; the partner brings the molecule.

A Platform Logic Built for Breadth

Medical cannabis is Alveon's first validated application area, and it serves as a meaningful proof of concept precisely because botanical extracts represent one of the more demanding formulation challenges in inhaled drug delivery: variable viscosity, complex phytochemical matrices, and a patient population that includes those with limited prior inhaler experience.

The SDV platform is, however, substance-agnostic by design. The core ceramic dosing engine can be adapted for a broad range of plant-based and phytopharmaceutical APIs without modification to the underlying technology architecture. This modularity means that pharmaceutical partners can license the platform as an enabling technology rather than build from first principles, especially when combined with the four core patents protecting the evaporator mechanism, dosing architecture, device design, and ceramic element properties.

The result is a development pathway that addresses one of the persistent bottlenecks in inhaled therapeutics: the gap between a promising molecule and a clinically deployable, regulatorily credible delivery system. Precision, in this context, is not a feature. It is the precondition for everything that follows.

---

To request the full ACTARMO Performance Report or discuss integration of your API into the SDV platform, contact us.